The viability of HER2 + cancer cells decreased significantly when exposed to trastuzumab and T-cells, compared to cancer cells exposed to trastuzumab without T-cells (p = 0.01), suggesting trastuzumab may trigger immune-mediated cytotoxicity [76]. Here, ERBB2 is linked to cancer.